Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (231-240 of 401) with videos related to

Pageof 41
Sort By:
Diabetes Care|December 14, 2022
Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES TrialRamzi A Ajjan, Simon R Heller, Colin C Everett, et al.
Atherosclerosis|December 14, 2019
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trialThor Ueland, Axel Åkerblom, Tatevik Ghukasyan, et al.
JAMA Cardiology|August 7, 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, et al.
Clinical Cardiology|June 10, 2017
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trialCharles V Pollack, Farideh Davoudi, Deborah B Diercks, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 31, 2015
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human ModelMark R Thomas, Samuel N Outteridge, Ramzi A Ajjan, et al.
International Journal of Cardiology|December 5, 2013
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
International Journal of Cardiology|July 10, 2014
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
International Journal of Cardiology|June 18, 2017
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC populationGuillaume Cayla, Frédéric Lapostolle, Patrick Ecollan, et al.
Circulation. Arrhythmia and Electrophysiology|January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) TrialAn H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Vascular Pharmacology|January 31, 2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromesWilliam A E Parker, Dominick J Angiolillo, Fabiana Rollini, et al.
Pageof 41

Showing results (231-240 of 401) with videos related to

Sort By:
Pageof 41
Diabetes Care|December 14, 2022
Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES TrialRamzi A Ajjan, Simon R Heller, Colin C Everett, et al.
Atherosclerosis|December 14, 2019
ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trialThor Ueland, Axel Åkerblom, Tatevik Ghukasyan, et al.
JAMA Cardiology|August 7, 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, et al.
Clinical Cardiology|June 10, 2017
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trialCharles V Pollack, Farideh Davoudi, Deborah B Diercks, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 31, 2015
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human ModelMark R Thomas, Samuel N Outteridge, Ramzi A Ajjan, et al.
International Journal of Cardiology|December 5, 2013
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
International Journal of Cardiology|July 10, 2014
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014Lars Wallentin, Richard C Becker, Christopher P Cannon, et al.
International Journal of Cardiology|June 18, 2017
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC populationGuillaume Cayla, Frédéric Lapostolle, Patrick Ecollan, et al.
Circulation. Arrhythmia and Electrophysiology|January 27, 2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) TrialAn H Bui, Christopher P Cannon, Philippe Gabriel Steg, et al.
Vascular Pharmacology|January 31, 2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromesWilliam A E Parker, Dominick J Angiolillo, Fabiana Rollini, et al.
Pageof 41